NO20030725D0 - Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin - Google Patents
Terapeutisk kombinasjon av CETP-inhibitor og atorvastatinInfo
- Publication number
- NO20030725D0 NO20030725D0 NO20030725A NO20030725A NO20030725D0 NO 20030725 D0 NO20030725 D0 NO 20030725D0 NO 20030725 A NO20030725 A NO 20030725A NO 20030725 A NO20030725 A NO 20030725A NO 20030725 D0 NO20030725 D0 NO 20030725D0
- Authority
- NO
- Norway
- Prior art keywords
- atorvastatin
- therapeutic combination
- cetp inhibitor
- cetp
- inhibitor
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22523800P | 2000-08-15 | 2000-08-15 | |
| PCT/IB2001/001309 WO2002013797A2 (en) | 2000-08-15 | 2001-07-23 | Therapeutic combination of a cetp inhibitor and atorvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20030725D0 true NO20030725D0 (no) | 2003-02-14 |
Family
ID=22844100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030725A NO20030725D0 (no) | 2000-08-15 | 2003-02-14 | Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020035125A1 (no) |
| EP (1) | EP1309329A2 (no) |
| JP (1) | JP2004506008A (no) |
| KR (1) | KR20030069983A (no) |
| CN (1) | CN1735416A (no) |
| AP (1) | AP2003002743A0 (no) |
| AU (1) | AU2001270937A1 (no) |
| BG (1) | BG107515A (no) |
| BR (1) | BR0113200A (no) |
| CA (1) | CA2419406A1 (no) |
| CZ (1) | CZ2003390A3 (no) |
| DZ (1) | DZ3409A1 (no) |
| EA (1) | EA200300155A1 (no) |
| EC (1) | ECSP034478A (no) |
| HR (1) | HRP20030104A2 (no) |
| HU (1) | HUP0303083A3 (no) |
| IL (1) | IL154348A0 (no) |
| IS (1) | IS6700A (no) |
| MX (1) | MXPA03001419A (no) |
| NO (1) | NO20030725D0 (no) |
| PA (1) | PA8525301A1 (no) |
| PE (1) | PE20020340A1 (no) |
| SK (1) | SK1742003A3 (no) |
| SV (1) | SV2003000600A (no) |
| TN (1) | TNSN01125A1 (no) |
| UY (1) | UY26883A1 (no) |
| WO (1) | WO2002013797A2 (no) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044459A1 (en) * | 2001-09-04 | 2003-03-06 | Pfizer Inc. | Biomodulated multiparticulate formulations |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| ES2310676T3 (es) * | 2002-12-20 | 2009-01-16 | Pfizer Products Inc. | Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa. |
| CA2509688A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| MXPA05012900A (es) * | 2003-05-30 | 2006-02-22 | Ranbaxy Lab Ltd | Derivados de pirrol sustituidos. |
| BRPI0413363A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase |
| JP4536061B2 (ja) | 2003-09-26 | 2010-09-01 | 日本たばこ産業株式会社 | レムナントリポ蛋白生成阻害方法 |
| AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| EP1845953A1 (en) * | 2005-02-03 | 2007-10-24 | Pfizer Products Incorporated | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| PL2334295T3 (pl) | 2008-09-02 | 2017-12-29 | Amarin Pharmaceuticals Ltd | Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| ES2769926T3 (es) | 2009-02-10 | 2020-06-29 | Amarin Pharmaceuticals Ie Ltd | Ester etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia |
| EP2424356B1 (en) | 2009-04-29 | 2017-08-23 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
| EP3563842A1 (en) | 2009-04-29 | 2019-11-06 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| EP3698781A1 (en) * | 2009-06-15 | 2020-08-26 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy |
| MX2012003555A (es) | 2009-09-23 | 2012-07-03 | Amarin Corp Plc | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| ES2993235T3 (en) | 2012-06-29 | 2024-12-26 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20240135078A (ko) | 2018-09-24 | 2024-09-10 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| AU2157400A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
-
2001
- 2001-07-23 EP EP01949825A patent/EP1309329A2/en not_active Ceased
- 2001-07-23 HU HU0303083A patent/HUP0303083A3/hu unknown
- 2001-07-23 IL IL15434801A patent/IL154348A0/xx unknown
- 2001-07-23 AU AU2001270937A patent/AU2001270937A1/en not_active Abandoned
- 2001-07-23 EA EA200300155A patent/EA200300155A1/ru unknown
- 2001-07-23 AP APAP/P/2003/002743A patent/AP2003002743A0/en unknown
- 2001-07-23 MX MXPA03001419A patent/MXPA03001419A/es not_active Application Discontinuation
- 2001-07-23 KR KR10-2003-7002220A patent/KR20030069983A/ko not_active Withdrawn
- 2001-07-23 HR HR20030104A patent/HRP20030104A2/hr not_active Application Discontinuation
- 2001-07-23 CN CNA018150667A patent/CN1735416A/zh active Pending
- 2001-07-23 DZ DZ013409A patent/DZ3409A1/fr active
- 2001-07-23 WO PCT/IB2001/001309 patent/WO2002013797A2/en not_active Application Discontinuation
- 2001-07-23 BR BR0113200-8A patent/BR0113200A/pt not_active IP Right Cessation
- 2001-07-23 SK SK174-2003A patent/SK1742003A3/sk not_active Application Discontinuation
- 2001-07-23 CZ CZ2003390A patent/CZ2003390A3/cs unknown
- 2001-07-23 JP JP2002518943A patent/JP2004506008A/ja not_active Withdrawn
- 2001-07-23 CA CA002419406A patent/CA2419406A1/en not_active Abandoned
- 2001-08-14 SV SV2001000600A patent/SV2003000600A/es not_active Application Discontinuation
- 2001-08-14 US US09/929,862 patent/US20020035125A1/en not_active Abandoned
- 2001-08-14 PE PE2001000810A patent/PE20020340A1/es not_active Application Discontinuation
- 2001-08-14 PA PA20018525301A patent/PA8525301A1/es unknown
- 2001-08-14 TN TNTNSN01125A patent/TNSN01125A1/fr unknown
- 2001-08-14 UY UY26883A patent/UY26883A1/es not_active Application Discontinuation
-
2003
- 2003-01-27 IS IS6700A patent/IS6700A/is unknown
- 2003-02-03 BG BG107515A patent/BG107515A/xx unknown
- 2003-02-13 EC EC2003004478A patent/ECSP034478A/es unknown
- 2003-02-14 NO NO20030725A patent/NO20030725D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN01125A1 (fr) | 2005-11-10 |
| HUP0303083A2 (hu) | 2003-12-29 |
| EA200300155A1 (ru) | 2003-08-28 |
| ECSP034478A (es) | 2003-03-31 |
| EP1309329A2 (en) | 2003-05-14 |
| BR0113200A (pt) | 2003-09-16 |
| SK1742003A3 (en) | 2004-06-08 |
| KR20030069983A (ko) | 2003-08-27 |
| US20020035125A1 (en) | 2002-03-21 |
| SV2003000600A (es) | 2003-01-13 |
| CA2419406A1 (en) | 2002-02-21 |
| DZ3409A1 (fr) | 2002-02-21 |
| AP2003002743A0 (en) | 2003-03-31 |
| MXPA03001419A (es) | 2003-06-06 |
| CN1735416A (zh) | 2006-02-15 |
| BG107515A (en) | 2003-09-30 |
| WO2002013797A2 (en) | 2002-02-21 |
| WO2002013797A3 (en) | 2003-03-13 |
| UY26883A1 (es) | 2002-03-22 |
| IL154348A0 (en) | 2003-09-17 |
| HUP0303083A3 (en) | 2005-05-30 |
| CZ2003390A3 (en) | 2004-03-17 |
| AU2001270937A1 (en) | 2002-02-25 |
| HRP20030104A2 (en) | 2003-04-30 |
| IS6700A (is) | 2003-01-27 |
| PA8525301A1 (es) | 2002-04-25 |
| JP2004506008A (ja) | 2004-02-26 |
| PE20020340A1 (es) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20030725D0 (no) | Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin | |
| DK1251848T3 (da) | Gyraseinhibitorer og anvendelse deraf | |
| NO20015773D0 (no) | Forhindring og behandling av amyloidogen sykdom | |
| NO20032668L (no) | Gyraseinhibitorer og anvendelser derav | |
| NO20020343D0 (no) | Kaspase-inhibitorer og anvendelse derav | |
| NO20022656D0 (no) | Caspaseinhibitorer og anvendelse derav | |
| NO20041582L (no) | Antistoffinhibitorer av GDF-8 og anvendelse derav | |
| NO20014560D0 (no) | Quinasoliner og terapautisk anvendelse derav | |
| NO20002784L (no) | Forhindring og behandling av amyloidogen sykdom | |
| NO20024295D0 (no) | Cyclopropyl-kondenserte pyrrolidin-baserte inhibitorer av dipeptidyl peptidase IV og fremgangsmåte | |
| DK1268425T3 (da) | Carbamatcaspaseinhibitorer og anvendelse deraf | |
| HUP0201463A3 (en) | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect and their use | |
| NO20015757L (no) | Felles salt av amlopidin og atorvastatin | |
| IS6477A (is) | Afleiður piperazíns og piperadíns | |
| IS7089A (is) | Lyfjasamsetningar amlódipíns og atórvastatíns | |
| NO20015274L (no) | ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav | |
| NO20033854D0 (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
| NO20040390L (no) | Krystallinske former VI og VII av atorvastatinkalsium. | |
| NO20011026D0 (no) | Matvare og fremgangsmÕte for fremstilling derav | |
| NO20015756D0 (no) | Felles promedikamenter av amlodipin og atorvastatin | |
| NO20030899L (no) | Anvendelse av salmeterol og fluticasonpropionat kombinasjon | |
| DK1228026T3 (da) | 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse | |
| NO20011703D0 (no) | Kondensator av ikke-brennbar og uhellsforhindrende type | |
| NO20026148L (no) | Medisiner for forhindring og behandling av neurodegenerative sykdommer | |
| NO20032821D0 (no) | Sea-trosy og beslektede fremgangsmåter |